T1abN0M0 HER2+ invasive breast cancer recurrence: Population-based cohort of 17,000+ consecutive breast cancers 2000-2006 at Kaiser Permanente Northern California (KPNC).

2011 ◽  
Vol 29 (15_suppl) ◽  
pp. 551-551 ◽  
Author(s):  
L. Fehrenbacher ◽  
P. Shiraz ◽  
M. Sattavat ◽  
A. Capra ◽  
C. Quesenberry ◽  
...  
2020 ◽  
Author(s):  
Teresa A'mar ◽  
J David Beatty ◽  
Catherine Fedorenko ◽  
Daniel Markowitz ◽  
Thomas Corey ◽  
...  

UNSTRUCTURED In “Incorporating Breast Cancer Recurrence Events Into Population-Based Cancer Registries Using Medical Claims: Cohort Study (J Med Internet Res Ca 2020;6(2):e18143)” the authors noted two errors. The metadata erroneously listed only Drs. A’mar and Etzioni as having contributed equally; this has been corrected to reflect that Drs. A’mar, Chubak, and Etzioni contributed equally. In addition, Dr. Chubak’s affiliation has been corrected from “Washington Health Research Institute, Kaiser Permanente” to “Kaiser Permanente Washington Health Research Institute.”


2011 ◽  
Vol 29 (27_suppl) ◽  
pp. 171-171 ◽  
Author(s):  
K. K. L. Yap ◽  
D. N. Efiom-Ekaha

171 Background: Oncotype DX Score is a 21-gene expression analysis that has been validated clinically as a reliable predictor of breast cancer recurrence for ER-positive, node-negative breast cancers. Obesity is recognized as a risk factor for many cancers, including breast cancer. Additionally obesity has been shown to be an independent prognostic factor in breast cancer. The primary objective of this study is to determine the correlation between obesity and Oncotype DX score, hence the relationship between obesity and breast cancer recurrence in ER-positive breast cancer. The secondary objective is to investigate the association between weight gain after diagnosis and breast cancer recurrence. Methods: An IRB-exempted retrospective chart review of female patients at Wellspan Group with ER-positive breast cancer who had Oncotype DX analysis in 2008 and 2009. Data collected included Oncotype DX score and BMI (at diagnosis, 6 months and 12 months). Data were analyzed to determine the correlation between Oncotype DX score and BMI at diagnosis, at 6 months and at 12 months. The correlation between Oncotype DX score and BMI changes at 12 months also was determined. Results: A total of 125 patients were identified; 103 had BMI recorded at diagnosis, 88 had BMI recorded at 6 months and 87 had BMI recorded at 12 months. Of these, we were able to determine the BMI changes at 12 months for 82 patients. The Pearson correlation scores were 0.091 (p = 0.361), 0.074 (p = 0.492), and 0.047 (p = 0.669) for BMI at diagnosis, at 6 months and at 12 months respectively. The Pearson correlation score was 0.007 (p = 0.948) for BMI changes at 12 months. Conclusions: Obesity and weight gain are not independent predictors of recurrence in patients with ER-positive breast cancer. The reported adverse prognostic associations may be more prominent in ER-negative breast cancers. This is consistent with the reports suggesting a higher rate of ER-negative, high-grade cancers in obese women as well as a greater magnitude of benefit from dietary and weight reduction interventions seen in women with ER-negative cancers.


2020 ◽  
Vol 38 (15_suppl) ◽  
pp. e12508-e12508
Author(s):  
Cecilia Munguti ◽  
Miriam Claire Mutebi ◽  
Mukuhi Ng'ang'a ◽  
Ronald Wasike

e12508 Background: Recurrence rates for early breast cancer vary in different studies from 7% to 18%. Recurrent breast cancer is associated with poorer outcome and higher mortality rates. The recurrence rate in the Kenyan population remains unknown despite high prevalence of known risk factors. Methods: Single institution retrospective study of all women (18 -75 years) treated for early breast cancer at a single center private tertiary unit from 2009 to 2017. Results: 239 patient records were reviewed. The mean age at diagnosis was 51 (SD13.1). 98% of women presented with a palpable breast lesion. The molecular sub-type’s prevalence was: ER/PR+ (76%), triple negative (12.1%), HER2+ (2.9%). The overall recurrence rate was 7.2%, 66% recurrences were loco-regional, while 27% were metastatic disease, with 61% of the recurrences being detected initially on clinical/ self-breast examination. 77% of the recurrences were in women with ER/PR+ molecular sub-types. Recurrences in women with DCIS (2/27) were invasive breast cancers. There were no identified risk factors on uni-variate and multivariate regression analysis which conferred a risk of breast cancer recurrence. Discussion: The mean age at diagnosis in this group is younger than the western average (65 - 75 years). Majority of the women presented with symptoms – a presentation that differs from that of countries with a national breast cancer screening program. The molecular distribution of breast cancers is comparable to western populations. Conclusions: Recurrence rate for early breast cancer in this series is 7.2%, which is comparable with documented western data, with majority of the recurrences being detected initially on clinical/self-breast examination.


2017 ◽  
Vol 165 (3) ◽  
pp. 633-643 ◽  
Author(s):  
Jake E. Thistle ◽  
Ylva Hellberg ◽  
Kristina Mortensen ◽  
Stephen Hamilton–Dutoit ◽  
Anders Kjærsgaard ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document